{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:43:04Z","timestamp":1787002984213,"version":"build-2736575974"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"10-11","license":[{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,1,6]],"date-time":"2020-01-06T00:00:00Z","timestamp":1578268800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C7838\/A25173"],"award-info":[{"award-number":["C7838\/A25173"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C52915\/A23946"],"award-info":[{"award-number":["C52915\/A23946"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Oncolytic virotherapies (OV) based on human adenoviral (HAdV) vectors hold significant promise for the treatment of advanced ovarian cancers where local, intraperitoneal delivery to tumour metastases is feasible, bypassing many complexities associated with intravascular delivery. The efficacy of HAdV-C5-based OV is hampered by a lack of tumour selectivity, where the primary receptor, hCAR, is commonly downregulated during malignant transformation. Conversely, folate receptor alpha (FR\u03b1) is highly expressed on ovarian cancer cells, providing a compelling target for tumour selective delivery of virotherapies. Here, we identify high-affinity FR\u03b1-binding oligopeptides for genetic incorporation into HAdV-C5 vectors. Biopanning identified a 12-mer linear peptide, DWSSWVYRDPQT, and two 7-mer cysteine-constrained peptides, CIGNSNTLC and CTVRTSAEC that bound FR\u03b1 in the context of the phage particle. Synthesised lead peptide, CTVRTSAEC, bound specifically to FR\u03b1 and could be competitively inhibited with folic acid. To assess the capacity of the elucidated FR\u03b1-binding oligopeptides to target OV to FR\u03b1, we genetically incorporated the peptides into the HAdV-C5 fiber-knob HI loop including in vectors genetically ablated for hCAR interactions. Unfortunately, the recombinant vectors failed to efficiently target transduction via FR\u03b1 due to defective intracellular trafficking following entry via FR\u03b1, indicating that whilst the peptides identified may have potential for applications for targeted drug delivery, they require additional refinement for targeted virotherapy applications.<\/jats:p>","DOI":"10.1038\/s41417-019-0156-0","type":"journal-article","created":{"date-parts":[[2020,1,5]],"date-time":"2020-01-05T19:08:57Z","timestamp":1578251337000},"page":"785-798","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Identification of folate receptor \u03b1 (FR\u03b1) binding oligopeptides and their evaluation for targeted virotherapy applications"],"prefix":"10.1038","volume":"27","author":[{"given":"Sarah L.","family":"Hulin-Curtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Davies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davor","family":"Nesti\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily A.","family":"Bates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander T.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tabitha G.","family":"Cunliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragomira","family":"Majhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Chester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9302-1761","authenticated-orcid":false,"given":"Alan L.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,1,6]]},"reference":[{"key":"156_CR1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ygyno.2018.08.016","volume":"151","author":"LC Peres","year":"2018","unstructured":"Peres LC, Cushing-Haugen KL, Anglesio M, Wicklund K, Bentley R, Berchuck A, et al. Histotype classification of ovarian carcinoma: a comparison of approaches. Gynecol Oncol. 2018;151:53\u201360.","journal-title":"Gynecol Oncol."},{"key":"156_CR2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3322\/caac.20113","volume":"61","author":"D Jelovac","year":"2011","unstructured":"Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183\u2013203.","journal-title":"CA Cancer J Clin"},{"key":"156_CR3","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","volume":"4","author":"CS Lee","year":"2017","unstructured":"Lee CS, Bishop ES, Zhang R, Yu X, Farina EM, Yan S, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4:43\u201363.","journal-title":"Genes Dis"},{"key":"156_CR4","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s11262-017-1498-z","volume":"53","author":"F J\u00f6nsson","year":"2017","unstructured":"J\u00f6nsson F, Kreppel F. Barriers to systemic application of virus-based vectors in gene therapy: lessons from adenovirus type 5. Virus Genes. 2017;53:692\u20139.","journal-title":"Virus Genes."},{"key":"156_CR5","doi-asserted-by":"crossref","unstructured":"Uusi-Kerttula H, Davies J, Coughlan L, Hulin-Curtis S, Jones R, Hanna L, et al. Pseudotyped av\u03b26 integrin-targeted adenovirus vectors for ovarian cancer therapies. Oncotarget. 2016;7:27926\u201337.","DOI":"10.18632\/oncotarget.8545"},{"key":"156_CR6","unstructured":"Zafar S, Beg S, Panda SK, Rahman M, Alharbi KS, Jain GK, et al. Novel therapeutic interventions in cancer treatment using protein and peptide-based targeted smart systems. Semin Cancer Biol. 2019;S1044-579X(19)30160-9, https:\/\/www.sciencedirect.com\/science\/article\/pii\/S1044579X19301609?via%3Dihub."},{"key":"156_CR7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1158\/1078-0432.CCR-07-1441","volume":"14","author":"K Cho","year":"2008","unstructured":"Cho K, Wang X, Nie S, Chen ZG, Shin DM. Therapeutic nanoparticles for drug delivery in cancer. Clin Cancer Res. 2008;14:1310\u20136.","journal-title":"Clin Cancer Res"},{"key":"156_CR8","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1158\/1078-0432.CCR-18-1089","volume":"24","author":"H Uusi-Kerttula","year":"2018","unstructured":"Uusi-Kerttula H, Davies JA, Thompson JM, Wongthida P, Evgin L, Shim KG, et al. Ad5NULL-A20: a tropism-modified, avb6 integrin-selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin Cancer Res. 2018;24:4215\u201324.","journal-title":"Clin Cancer Res"},{"key":"156_CR9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1158\/0008-5472.CAN-07-2307","volume":"68","author":"LA Van Aarsen","year":"2008","unstructured":"Van Aarsen LA, Leone DR, Ho S, Dolinski BM, McCoon PE, LePage DJ, et al. Antibody-mediated blockade of integrin alpha v beta 6 inhibits tumor progression in vivo by a transforming growth factor-beta-regulated mechanism. Cancer Res. 2008;68:561\u201370.","journal-title":"Cancer Res."},{"key":"156_CR10","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","volume":"34","author":"IB Vergote","year":"2015","unstructured":"Vergote IB, Marth C, Coleman RL. Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications. Cancer Metastasis Rev. 2015;34:41\u201352.","journal-title":"Cancer Metastasis Rev"},{"key":"156_CR11","doi-asserted-by":"publisher","unstructured":"Zwicke GL, Mansoori GA, Jeffery CJ. Utilizing the folate receptor for active targeting of cancer nanotherapeutics. Nano Rev. 2012;3. https:\/\/doi.org\/10.3402\/nano.v3i0.18496.","DOI":"10.3402\/nano.v3i0.18496."},{"key":"156_CR12","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0168-3659(01)00316-9","volume":"74","author":"JA Reddy","year":"2001","unstructured":"Reddy JA, Clapp DW, Low PS. Retargeting of viral vectors to the folate receptor endocytic pathway. J Control Release. 2001;74:77\u201382.","journal-title":"J Control Release"},{"key":"156_CR13","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/S0167-7799(00)88997-0","volume":"13","author":"RC Ladner","year":"1995","unstructured":"Ladner RC. Constrained peptides as binding entities. Trends Biotechnol. 1995;13:426\u201330.","journal-title":"Trends Biotechnol."},{"key":"156_CR14","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2174\/187152006774755492","volume":"6","author":"TI Samoylova","year":"2006","unstructured":"Samoylova TI, Morrison NE, Globa LP, Cox NR. Peptide phage display: opportunities for development of personalized anti-cancer strategies. Anticancer Agents Med Chem. 2006;6:9\u201317.","journal-title":"Anticancer Agents Med Chem"},{"key":"156_CR15","doi-asserted-by":"crossref","first-page":"857","DOI":"10.3390\/molecules16010857","volume":"16","author":"P Molek","year":"2011","unstructured":"Molek P, Strukelj B, Bratkovic T. Peptide phage display as a tool for drug discovery: targeting membrane receptors. Molecules. 2011;16:857\u201387.","journal-title":"Molecules."},{"key":"156_CR16","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/17460441.2.4.525","volume":"2","author":"LR Krumpe","year":"2007","unstructured":"Krumpe LR, Mori T. Potential of phage-displayed peptide library technology to identify functional targeting peptides. Expert Opin Drug Discov. 2007;2:525.","journal-title":"Expert Opin Drug Discov"},{"key":"156_CR17","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.2174\/1381612043383944","volume":"10","author":"T Mori","year":"2004","unstructured":"Mori T. Cancer-specific ligands identified from screening of peptide-display libraries. Curr Pharm Des. 2004;10:2335\u201343.","journal-title":"Curr Pharm Des"},{"key":"156_CR18","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.2174\/1389557516666160219121836","volume":"17","author":"R Soudy","year":"2017","unstructured":"Soudy R, Byeon N, Raghuwanshi Y, Ahmed S, Lavasanifar A, Kaur K. Engineered peptides for applications in cancer-targeted drug delivery and tumor detection. Mini Rev Med Chem. 2017;17:1696\u2013712.","journal-title":"Mini Rev Med Chem"},{"key":"156_CR19","doi-asserted-by":"crossref","first-page":"7724","DOI":"10.1158\/0008-5472.CAN-05-4441","volume":"66","author":"DN Krag","year":"2006","unstructured":"Krag DN, Shukla GS, Shen GP, Pero S, Ashikaga T, Fuller S, et al. Selection of tumor-binding ligands in cancer patients with phage display libraries. Cancer Res. 2006;66:7724\u201333.","journal-title":"Cancer Res."},{"key":"156_CR20","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1097\/GCO.0000000000000515","volume":"31","author":"D Stewart","year":"2019","unstructured":"Stewart D, Cristea M. Antibody-drug conjugates for ovarian cancer: current clinical development. Curr Opin Obstet Gynecol. 2019;31:18\u201323.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"156_CR21","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00280-017-3501-8","volume":"81","author":"AJ Cortez","year":"2018","unstructured":"Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81:17\u201338.","journal-title":"Cancer Chemother Pharmacol"},{"key":"156_CR22","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1089\/hum.2009.038","volume":"20","author":"N Bayo-Puxan","year":"2009","unstructured":"Bayo-Puxan N, Gimenez-Alejandre M, Lavilla-Alonso S, Gros A, Cascallo M, Hemminki A, et al. Replacement of adenovirus type 5 fiber shaft heparan sulfate proteoglycan-binding domain with RGD for improved tumor infectivity and targeting. Hum Gene Ther. 2009;20:1214\u201321.","journal-title":"Hum Gene Ther"},{"key":"156_CR23","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbrc.2006.07.051","volume":"348","author":"D Majhen","year":"2006","unstructured":"Majhen D, Gabrilovac J, Eloit M, Richardson J, Ambriovi\u0107-Ristov A. Disulfide bond formation in NGR fiber-modified adenovirus is essential for retargeting to aminopeptidase N. Biochem Biophys Res Commun. 2006;348:278\u201387.","journal-title":"Biochem Biophys Res Commun"},{"key":"156_CR24","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1089\/hum.2015.015","volume":"26","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, Legut M, Davies J, Jones R, Hudson E, Hanna L, et al. Incorporation of peptides targeting EGFR and FGFR1 into the adenoviral fiber knob domain and their evaluation as targeted cancer therapies. Hum Gene Ther. 2015;26:320\u20139.","journal-title":"Hum Gene Ther"},{"key":"156_CR25","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1111\/cas.13228","volume":"108","author":"Y Yamamoto","year":"2017","unstructured":"Yamamoto Y, Nagasato M, Yoshida T, Aoki K. Recent advances in genetic modification of adenovirus vectors for cancer treatment. Cancer Sci. 2017;108:831\u20137.","journal-title":"Cancer Sci."},{"key":"156_CR26","doi-asserted-by":"crossref","first-page":"W296","DOI":"10.1093\/nar\/gky427","volume":"46","author":"A Waterhouse","year":"2018","unstructured":"Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res. 2018;46:W296\u2013303.","journal-title":"Nucleic Acids Res."},{"key":"156_CR27","volume":"10","author":"AT Baker","year":"2019","unstructured":"Baker AT, Greenshields-Watson A, Coughlan L, Davies JA, Uusi-Kerttula H, Cole DK, et al. Diversity within the adenovirus fiber knob hypervariable loops influences primary receptor interactions. Nat Commun. 2019;10:741.","journal-title":"Nat Commun."},{"key":"156_CR28","doi-asserted-by":"crossref","unstructured":"Baugh EH, Lyskov S, Weitzner BD, Gray JJ. Real-time PyMOL visualization for Rosetta and PyRosetta. PLoS ONE. 2011;6:e21931.","DOI":"10.1371\/journal.pone.0021931"},{"key":"156_CR29","doi-asserted-by":"crossref","first-page":"659","DOI":"10.2144\/000112993","volume":"45","author":"RJ Stanton","year":"2008","unstructured":"Stanton RJ, McSharry BP, Armstrong M, Tomasec P, Wilkinson GW. Re-engineering adenovirus vector systems to enable high-throughput analyses of gene function. Biotechniques. 2008;45:659\u201362. 64-8","journal-title":"Biotechniques."},{"key":"156_CR30","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1006\/mthe.2001.0489","volume":"4","author":"SA Nicklin","year":"2001","unstructured":"Nicklin SA, Von Seggern DJ, Work LM, Pek DC, Dominiczak AF, Nemerow GR, et al. Ablating adenovirus type 5 fiber-CAR binding and HI loop insertion of the SIGYPLP peptide generate an endothelial cell-selective adenovirus. Mol Ther. 2001;4:534\u201342.","journal-title":"Mol Ther."},{"key":"156_CR31","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1126\/science.275.5304.1320","volume":"275","author":"JM Bergelson","year":"1997","unstructured":"Bergelson JM, Cunningham JA, Droguett G, Kurt-Jones EA, Krithivas A, Hong JS, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. Science. 1997;275:1320\u20133.","journal-title":"Science"},{"key":"156_CR32","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/0092-8674(93)90231-E","volume":"73","author":"TJ Wickham","year":"1993","unstructured":"Wickham TJ, Mathias P, Cheresh DA, Nemerow GR. Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993;73:309\u201319.","journal-title":"Cell."},{"key":"156_CR33","doi-asserted-by":"crossref","first-page":"4654","DOI":"10.1128\/JVI.02696-06","volume":"81","author":"P Abbink","year":"2007","unstructured":"Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, Smits S, et al. Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007;81:4654\u201363.","journal-title":"J Virol"},{"key":"156_CR34","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/JVI.01878-08","volume":"83","author":"AL Parker","year":"2009","unstructured":"Parker AL, Waddington SN, Buckley SM, Custers J, Havenga MJ, van Rooijen N, et al. Effect of neutralizing sera on factor x-mediated adenovirus serotype 5 gene transfer. J Virol. 2009;83:479\u201383.","journal-title":"J Virol."},{"key":"156_CR35","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1182\/blood-2008-09-178459","volume":"113","author":"RC Carlisle","year":"2009","unstructured":"Carlisle RC, Di Y, Cerny AM, Sonnen AF, Sim RB, Green NK, et al. Human erythrocytes bind and inactivate type 5 adenovirus by presenting Coxsackie virus-adenovirus receptor and complement receptor 1. Blood. 2009;113:1909\u201318.","journal-title":"Blood."},{"key":"156_CR36","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymthe.2006.01.003","volume":"14","author":"M Lyons","year":"2006","unstructured":"Lyons M, Onion D, Green NK, Aslan K, Rajaratnam R, Bazan-Peregrino M, et al. Adenovirus type 5 interactions with human blood cells may compromise systemic delivery. Mol Ther. 2006;14:118\u201328.","journal-title":"Mol Ther."},{"key":"156_CR37","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000277","volume":"5","author":"E Seiradake","year":"2009","unstructured":"Seiradake E, Henaff D, Wodrich H, Billet O, Perreau M, Hippert C, et al. The cell adhesion molecule \"CAR\" and sialic acid on human erythrocytes influence adenovirus in vivo biodistribution. PLoS Pathog. 2009;5:e1000277.","journal-title":"PLoS Pathog."},{"key":"156_CR38","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1182\/blood-2006-04-008532","volume":"108","author":"AL Parker","year":"2006","unstructured":"Parker AL, Waddington SN, Nicol CG, Shayakhmetov DM, Buckley SM, Denby L, et al. Multiple vitamin K-dependent coagulation zymogens promote adenovirus-mediated gene delivery to hepatocytes. Blood. 2006;108:2554\u201361.","journal-title":"Blood."},{"key":"156_CR39","first-page":"439","volume":"10","author":"AL Parker","year":"2008","unstructured":"Parker AL, Nicklin SA, Baker AH. Interactions of adenovirus vectors with blood: implications for intravascular gene therapy applications. Curr Opin Mol Ther. 2008;10:439\u201348.","journal-title":"Curr Opin Mol Ther"},{"key":"156_CR40","doi-asserted-by":"crossref","first-page":"6009","DOI":"10.3390\/v7112923","volume":"7","author":"H Uusi-Kerttula","year":"2015","unstructured":"Uusi-Kerttula H, Hulin-Curtis S, Davies J, Parker AL. Oncolytic adenovirus: strategies and insights for vector design and immuno-oncolytic applications. Viruses. 2015;7:6009\u201342.","journal-title":"Viruses."},{"key":"156_CR41","doi-asserted-by":"crossref","DOI":"10.1007\/s12032-014-0110-9","volume":"31","author":"B Bakhshinejad","year":"2014","unstructured":"Bakhshinejad B, Karimi M, Sadeghizadeh M. Bacteriophages and medical oncology: targeted gene therapy of cancer. Med Oncol. 2014;31:110.","journal-title":"Med Oncol."},{"key":"156_CR42","volume":"8","author":"L Xing","year":"2018","unstructured":"Xing L, Xu Y, Sun K, Wang H, Zhang F, Zhou Z, et al. Identification of a peptide for folate receptor alpha by phage display and its tumor targeting activity in ovary cancer xenograft. Sci Rep. 2018;8:8426.","journal-title":"Sci Rep."},{"key":"156_CR43","volume":"15","author":"C Zhou","year":"2015","unstructured":"Zhou C, Kang J, Wang X, Wei W, Jiang W. Phage display screening identifies a novel peptide to suppress ovarian cancer cells in vitro and in vivo in mouse models. BMC Cancer. 2015;15:889.","journal-title":"BMC Cancer."},{"key":"156_CR44","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.3892\/ol.2016.4549","volume":"11","author":"L Wang","year":"2016","unstructured":"Wang L, Hu Y, Li W, Wang F, Lu X, Han X, et al. Identification of a peptide specifically targeting ovarian cancer by the screening of a phage display peptide library. Oncol Lett. 2016;11:4022\u20136.","journal-title":"Oncol Lett"},{"key":"156_CR45","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1021\/acs.bioconjchem.5b00178","volume":"26","author":"Z Han","year":"2015","unstructured":"Han Z, Zhou Z, Shi X, Wang J, Wu X, Sun D, et al. EDB fibronectin specific peptide for prostate cancer targeting. Bioconjug Chem. 2015;26:830\u20138.","journal-title":"Bioconjug Chem."},{"key":"156_CR46","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1007\/s00726-014-1852-6","volume":"47","author":"KJ Lee","year":"2015","unstructured":"Lee KJ, Lee JH, Chung HK, Choi J, Park J, Park SS, et al. Novel peptides functionally targeting in vivo human lung cancer discovered by in vivo peptide displayed phage screening. Amino Acids. 2015;47:281\u20139.","journal-title":"Amino Acids."},{"key":"156_CR47","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/bjc.2017.366","volume":"118","author":"L Hou","year":"2018","unstructured":"Hou L, Zhu D, Liang Y, Tian X, Li L, Wang P, et al. Identification of a specific peptide binding to colon cancer cells from a phage-displayed peptide library. Br J Cancer. 2018;118:79\u201387.","journal-title":"Br J Cancer"},{"key":"156_CR48","doi-asserted-by":"crossref","first-page":"790","DOI":"10.3390\/molecules16010790","volume":"16","author":"M Vodnik","year":"2011","unstructured":"Vodnik M, Zager U, Strukelj B, Lunder M. Phage display: selecting straws instead of a needle from a haystack. Molecules. 2011;16:790\u2013817.","journal-title":"Molecules."},{"key":"156_CR49","doi-asserted-by":"crossref","first-page":"9706","DOI":"10.1128\/JVI.72.12.9706-9713.1998","volume":"72","author":"I Dmitriev","year":"1998","unstructured":"Dmitriev I, Krasnykh V, Miller CR, Wang M, Kashentseva E, Mikheeva G, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. J Virol. 1998;72:9706\u201313.","journal-title":"J Virol."},{"key":"156_CR50","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1128\/JVI.72.3.1844-1852.1998","volume":"72","author":"V Krasnykh","year":"1998","unstructured":"Krasnykh V, Dmitriev I, Mikheeva G, Miller CR, Belousova N, Curiel DT. Characterization of an adenovirus vector containing a heterologous peptide epitope in the HI loop of the fiber knob. J Virol. 1998;72:1844\u201352.","journal-title":"J Virol."},{"key":"156_CR51","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/cgt.2012.23","volume":"19","author":"EN Ballard","year":"2012","unstructured":"Ballard EN, Trinh VT, Hogg RT, Gerard RD. Peptide targeting of adenoviral vectors to augment tumor gene transfer. Cancer Gene Ther. 2012;19:476\u201388.","journal-title":"Cancer Gene Ther"},{"key":"156_CR52","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1038\/sj.gt.3302084","volume":"10","author":"R Bilbao","year":"2003","unstructured":"Bilbao R, Reay DP, Hughes T, Biermann V, Volpers C, Goldberg L, et al. Fetal muscle gene transfer is not enhanced by an RGD capsid modification to high-capacity adenoviral vectors. Gene Ther. 2003;10:1821\u20139.","journal-title":"Gene Ther."}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41417-019-0156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-019-0156-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41417-019-0156-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:10:39Z","timestamp":1684602639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-019-0156-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,6]]},"references-count":52,"journal-issue":{"issue":"10-11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["156"],"URL":"https:\/\/doi.org\/10.1038\/s41417-019-0156-0","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,1,6]]},"assertion":[{"value":"9 September 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}